Verano Holdings (VRNO) Depreciation & Amortization (CF) (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Depreciation & Amortization (CF) of $29.2 million for Q1 2026, down 8.19% year-over-year from $31.8 million in Q1 2025, and little changed quarter-over-quarter from $29.3 million in Q4 2025.
Verano Holdings (VRNO) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $29.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 8.19% year-over-year to $29.2 million; the TTM figure through Mar 2026 stood at $121.6 million (down 10.56% YoY), while the FY2025 annual figure was $124.2 million, down 11.1% from the prior year.
- Depreciation & Amortization (CF) steadied at $29.2 million in Q1 2026 per VRNO's latest filing, from $29.3 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $36.9 million in Q3 2024 and bottomed at $29.2 million in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $33.9 million across 5 years, with a median of $35.2 million in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 46.15% — and 2025, when it slipped 14.39%.
- Verano Holdings' Depreciation & Amortization (CF) stood at $35.2 million in 2022, then advanced by 1.19% to $35.6 million in 2023, then retreated by 11.41% to $31.5 million in 2024, then declined by 6.97% to $29.3 million in 2025, then retreated by 0.44% to $29.2 million in 2026.
- Business Quant data shows VRNO's Depreciation & Amortization (CF) at $29.2 million in Q1 2026, $29.3 million in Q4 2025, and $31.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Verano Holdings | 449.04 Mn | 363.85 Mn | 99.70 Mn | 29.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.43 Mn |
| Jun 30, 2026 | 29.43 Mn |
| Mar 31, 2026 | 29.19 Mn |
| Mar 31, 2026 | 29.19 Mn |
| Dec 31, 2025 | 29.32 Mn |
| Dec 31, 2025 | 29.32 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Jun 30, 2025 | 31.49 Mn |
| Jun 30, 2025 | 31.49 Mn |
| Mar 31, 2025 | 31.79 Mn |
| Mar 31, 2025 | 31.79 Mn |
| Dec 31, 2024 | 31.51 Mn |
| Dec 31, 2024 | 31.51 Mn |
| Sep 30, 2024 | 36.87 Mn |
| Sep 30, 2024 | 36.87 Mn |
| Jun 30, 2024 | 35.73 Mn |
| Jun 30, 2024 | 35.73 Mn |
| Mar 31, 2024 | 35.55 Mn |
| Mar 31, 2024 | 35.55 Mn |